Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: An in vitro evaluation

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 3, 2014, Pages 1294-1301

  Rizk, Matthew L ^a   Houle, Robert ^a   Chan, Grace Hoyee ^a   Hafey, Mike ^a   Rhee, Elizabeth G ^a   Chu, Xiaoyan ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN A; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PROBENECID; PROTEIN MATE2 K; QUINIDINE; RALTEGRAVIR; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; EVALUATION STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DOGS; DRUG INTERACTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MEMBRANE TRANSPORT PROTEINS; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANIC CATION TRANSPORT PROTEINS; ORGANIC CATION TRANSPORTER 1; PYRROLIDINONES;

EID: 84896895870     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02049-13     Document Type: Article

References (41)

1. Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. 2013. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging 30:613-628.
2. Zhou SF. 2008. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 9:310-322. http://dx.doi.org/10. 2174/138920008784220664.
3. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. 2007. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit. 29:687-710. http://dx.doi.org/10.1097/FTD.0b013e31815c16f5. (Pubitemid 350190847)
4. Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. 2009. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab. Dispos. 37:1793-1796. http://dx.doi.org/10.1124/dmd.109.027706.
5. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, Feinberg J, Sherman KE. 2001. Mechanism of indinavir-induced hyperbilirubinemia. Proc. Natl. Acad. Sci. U. S. A. 98:12671-12676. http://dx.doi.org/10.1073/pnas.231140698. (Pubitemid 33020004)
6. Griffin L, Annaert P, Brouwer KL. 2011. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J. Pharmaceut. Sci. 100:3636-3654. http://dx.doi.org/10.1002/jps. 22655.
7. Zembruski NC, Buchel G, Jodicke L, Herzog M, Haefeli WE, Weiss J. 2011. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro. J. Antimicrob. Chemother. 66:802-812. http://dx.doi.org/10.1093/jac/dkq501.
8. Lin JH, Yamazaki M. 2003. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab. Rev. 35:417-454. http://dx.doi.org/10.1081/DMR-120026871. (Pubitemid 38018115)
9. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, Sora ES, James CE, Gibbons S, Bray PG, Back DJ, Khoo SH, Owen A. 2010. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet. Genomics 20:112-120. http://dx.doi.org/10.1097/FPC.0b013e328335b02d.
10. Annaert P, Ye ZW, Stieger B, Augustijns P. 2010. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica 40:163-176. http://dx.doi.org/10.3109/00498250903509375.
11. Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, Webster LO, Harmon KA, Clarke JD, Polli JW. 2013. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab. Dispos. 41:353-361. http://dx.doi.org/10.1124/dmd.112.048918.
12. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365. http://dx.doi.org/10. 1056/NEJMoa0708978.
13. Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, Gonzalez CJ, Danovich RM, Wan H, Zhao J, Meibohm AR, Strohmaier KM, Harvey CM, Isaacs RD, Nguyen BY. 2010. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. J. Acquir. Immune Defic. Syndr. 53:456-463. http://dx.doi.org/10.1097/ QAI.0b013e3181c9c967.
14. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269. http://dx.doi.org/10.1016/S0140-6736(07)60597-2. (Pubitemid 46553846)
15. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354. http://dx.doi.org/10.1056/ NEJMoa0708975.
16. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P. 2009. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374:796-806. http://dx.doi.org/10.1016/S0140-6736(09)60918-1.
17. Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P. 2010. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J. Acquir. Immune Defic. Syndr. 55:39-48. http://dx.doi.org/10.1097/QAI.0b013e3181da1287.
18. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515. http://dx.doi.org/10.1097/QAI.0b013e31802b4956. (Pubitemid 44885615)
19. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133. http://dx.doi.org/10.1097/ QAI.0b013e318157131c. (Pubitemid 47482607)
20. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H. 2009. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J. Acquir. Immune Defic. Syndr. 52:350-356. http://dx.doi.org/10.1097/QAI.0b013e3181b064b0.
21. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, Wenning LA. 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 35:1657-1663. http://dx.doi.org/10.1124/dmd.107.016196. (Pubitemid 47296061)
22. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. 2011. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J. Clin. Pharmacol. 51:1376-1402. http://dx.doi.org/10.1177/ 0091270010387428.
23. Iwamoto M, Wenning LA, Mistry GC, Petry AS, Liou SY, Ghosh K, Breidinger S, Azrolan N, Gutierrez MJ, Bridson WE, Stone JA, Gottesdiener KM, Wagner JA. 2008. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin. Infect. Dis. 47:137-140. http://dx.doi.org/10.1086/588794. (Pubitemid 351920602)
24. Moss DM, Kwan WS, Liptrott NJ, Smith DL, Siccardi M, Khoo SH, Back DJ, Owen A. 2011. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob. Agents Chemother. 55:879-887. http://dx.doi.org/10.1128/AAC.00623-10.
25. Borst P, Evers R, Kool M, Wijnholds J. 2000. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:1295-1302. http://dx.doi.org/10.1093/jnci/92.16.1295. (Pubitemid 30662093)
26. European Medicine Agency (EMA). 21 June 2012. Guideline on the investigation of drug interactions. EMA, London, United Kingdom.
27. U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER). February 2012.Guidance for industry, drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. HHS, Washington, DC.
28. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat. Rev. 9:215-236.
29. Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, Zhang L. 2013. Emerging transporters of clinical importance: an update from the international transporter consortium. Clin. Pharmacol. Therapeut. 94:52-63. http://dx.doi.org/10.1038/clpt.2013.74.
30. Monteagudo E, Fonsi M, Chu X, Bleasby K, Evers R, Pucci V, Orsale MV, Cianetti S, Ferrara M, Harper S, Laufer R, Rowley M, Summa V. 2010. The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease. Xenobiotica 40:826-839. http://dx.doi.org/10.3109/00498254.2010. 519061.
31. Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R. 2007. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J. Pharmacol. Exp. Ther. 321:673-683. http://dx.doi.org/10.1124/jpet.106.116517. (Pubitemid 46624514)
32. Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, Green MD, Kuo Y, Liang Y, Maciolek CM, Palamanda J, Evers R, Prueksaritanont T. 2013. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab. Dispos. 41:668-681. http://dx.doi.org/10.1124/dmd.112.049668.
33. Chu XY, Huskey SE, Braun MP, Sarkadi B, Evans DC, Evers R. 2004. Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J. Pharmacol. Exp. Ther. 309:156-164. http://dx.doi.org/10.1124/jpet.103.062091. (Pubitemid 38393126)
34. Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2006. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Disp. 34:1229-1236. http://dx.doi.org/10.1124/dmd.106.009290.
35. Rizk ML, Hang Y, Luo WL, Su J, Zhao J, Campbell H, Nguyen BY, Sklar P, Eron JJ, Jr., Wenning L. 2012. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob. Agents Chemother. 56:3101-3106. http://dx.doi.org/10.1128/ AAC.06417-11.
36. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. 2008. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 9:415-422. http://dx.doi.org/10.2217/14622416.9.4.415. (Pubitemid 351803926)
37. Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, Gottesdiener KM, Chen J, Teppler H, Wagner JA, Stone JA, Iwamoto M. 2008. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob. Agents Chemother. 52:3253-3258. http://dx.doi.org/10.1128/AAC.00005-08.
38. Yonezawa A, Inui K. 2011. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Brit. J. Pharmacol. 164:1817-1825. http://dx.doi.org/10.1111/ j.1476-5381.2011.01394.x.
39. Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T, Cannon C, Muster H, Piscitelli SC. 2012. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Brit. J. Clin. Pharmacol. 75:990-996. http://dx.doi.org/10.1111/j.1365-2125.2012.04440.x.
40. German P, Liu HC, Szwarcberg J, Hepner M, Andrews J, Kearney BP, Mathias A. 2012. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J. Acquir. Immune Defic. Syndr. 61:32-40. http://dx.doi.org/10.1097/QAI.0b013e3182645648.
41. Burckhardt G, Burckhardt BC. 2011. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb. Exp. Pharmacol. (201):29-104. http://dx.doi.org/10.1007/978-3-642-14541-4-2.